Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 32  |  Issue : 4  |  Page : 1490-1495

CD62L expression in patients with chronic lymphocytic leukemia

1 Department of Clinical Pathology, Faulty of Medicine, Menoufia University, Shebin El Kom, Egypt
2 Department of Clinical Oncology, Faulty of Medicine, Menoufia University, Shebin El Kom, Egypt
3 Department of Clinical Pathology, Shebin Elkom Fever Hospital, Shebin El Kom, Egypt

Correspondence Address:
Sanaa S. M. Gebril
Shebin El Kom City 32717, Menoufia Government
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mmj.mmj_587_17

Rights and Permissions

Objective The objective of this study was to evaluate CD62L expression in chronic lymphocytic leukemia (CLL) and its effect on survival of malignant B cells. Background CLL is the most common adult leukemia and often presents as an early-stage disease. It could be stable for many years with no or minimal intervention. CD62L is one of the selectin family of adhesion molecules that plays an important role in the trafficking/homing of lymphocytes to the lymph node. Patients and methods This study was conducted on 35 patients with CLL and 15 age-matched and sex-matched healthy individuals as a control group. All patients were subjected to full history taking, clinical examination, and laboratory investigations. CD62L/CD19 expression on lymphocytes was measured for all the study participants using flow cytometry technique before and after cell culture. Results CD62L/CD19 expression increased minimally in controls at day 7 compared with day 0 (mean ± SD = 33.9 ± 5.3 and 18.03 ± 3.4, respectively) (P < 0.001), whereas the diseased group showed marked elevation at day 7 than day 0 (mean ± SD = 90.7 ± 6.4 and 36.9 ± 17.2, respectively) (P < 0.001). CD62L/CD19 expression in patients was higher than the controls at day 0 (mean ± SD = 36.9 ± 17.2 and 18.03 ± 3.4, respectively) and showed increase of approximately threefolds at day 7 (mean ± SD: 90.7 ± 6.4 and 33.9 ± 5.3, respectively) (P < 0.001). Conclusion There is high expression of CD62L on lymphocytic cells in patients with CLL associated with increased survival of malignant B cells.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal